ArticlePancreas
Outcomes of Surveillance Program for Individuals at High-Risk of Pancreatic Adenocarcinoma.
Article in Pancreas. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIndividuals at high-risk (HRI) of developing pancreatic adenocarcinoma (PDAC) are offered intensive screening to detect PDAC at an early, curable stage. There are scant data on how HRI PDAC screening programs perform in clinical practice outside of large, prospective cohort studies. This study assessed the screening patterns, outcomes, and adherence of HRIs participating in a structured PDAC screening program.
methodsWe conducted a retrospective cohort study of HRIs at a single, quaternary-care referral center between 2009 and 2025. Based on risk factors, patients were offered structured testing with noninvasive imaging [most commonly magnetic resonance imaging (MRI)] and/or endoscopic ultrasound (EUS). Demographic and clinical information were obtained through chart review. Adherence rates were calculated, and a multivariable analysis was conducted to identify factors associated with adherence.
resultsA total of 316 patients met high-risk criteria and underwent screening. Seven PDACs were detected during a mean cohort follow-up of 2.5 years; 6 early-stage PDACs (4 stage I, 2 stage II) were detected during surveillance, and 1 stage III PDAC was diagnosed due to symptoms in a patient nonadherent to screening. Seven patients underwent surgical resection, including 4 with PDAC and 3 with worrisome lesions on imaging or endoscopic ultrasound (2 high-risk cystic lesions and 1 PanIN-IB). There was 1 death from PDAC in a patient with stage IA disease who did not undergo resection. The mean adherence rate for the cohort was 76.5% over 3.8 years. Individuals with pathogenic germline variants demonstrated higher adherence ( P =0.02).
conclusionA PDAC screening program for HRIs identified early-stage PDAC in an important proportion of patients. While overall adherence rates are high, additional research is needed to identify barriers affecting patient adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.